Showing results (371-380 of 392) with videos related to

Sort By:
Pageof 40
Nature Genetics|August 4, 2022
Molecular map of chronic lymphocytic leukemia and its impact on outcomeBinyamin A Knisbacher, Ziao Lin, Cynthia K Hahn, et al.
The Lancet. Haematology|October 22, 2017
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Haematologica|July 9, 2016
Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysisKebria Hezaveh, Andreas Kloetgen, Stephan H Bernhart, et al.
Blood|April 29, 2024
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemiaPhilipp M Roessner, Isabelle Seufert, Vicente Chapaprieta, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER StudyLorenz Thurner, Marita Ziepert, Christian Berdel, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2020
IGLV3-21 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signalingPalash C Maity, Mayas Bilal, Marvyn T Koning, et al.
Blood|April 9, 2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemiaAdalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, et al.
Leukemia|May 13, 2022
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Nature Communications|October 20, 2022
Proteogenomics refines the molecular classification of chronic lymphocytic leukemiaSophie A Herbst, Mattias Vesterlund, Alexander J Helmboldt, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
Pageof 40